Abstract: The invention relates to novel nutraceutical and pharmaceutical compositions comprising at least a compound of the general formula (I), wherein R1 and R2 are independently from each other C1-8-alk(en)yl and R3 and R4 are independently from each other hydroxy or C1-8-alkyloxy, as well as to the use of these compositions for the treatment, co-treatment or prevention of joint disorders.

Abstract: Use of biotin, preferably in a combination of biotin and (-)-epigallocatechin gallate (EGCG) in a specific ratio, to prevent sunlight-induced aging (photoaging) of the skin.

Abstract: The present invention relates to novel composition for the treatment, co-treatment or prevention of inflammatory disorders comprising an effective amount of carnosic acid 12-methylether.

Abstract: The present invention relates to novel compositions comprising hydroxytyrosol and/or oleuropein (I) and at least one additional component e.g. selected from the group of ligustilide, oleuropein aglycone, magnolol, honokiol, genistein, resveratrol, EGCG, magnolia bark extract, cashew fruit extract and Glycyrrhiza foetida as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.

Abstract: The present invention refers to the use of at least one tricyclic diterpenes for the manufacture of a nutraceutical or pharmaceutical for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders.

Abstract: The present invention relates to novel compositions comprising rosehip and at least one additional component e.g. selected from ligustilide, oleuropein (I), oleuropein aglycone (II), hydroxytyrosol, genistein, magnolol, honokiol, magnolia bark extract, cashew fruit extract and Glycyrrhiza foetida as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.

Abstract: The present invention is directed inter alia to the use of at least one compound selected from the group consisting of (?)-epigallocatechin gallate, resveratrol, eicosapentaenoic acid, docosahexaenioic acid, rose hip extract/concentrate, hydroxytyrosol, lycopene, lutein, ?-cryptoxanthin, zeaxanithin and derivatives thereof, for the treatment of cellulite, for the prevention of the development of mild cellulite, for the prevention of the progression of mild cellulite to severe cellulite, for smoothening the micro relief of the skin, for maintaining or increasing the tensile properties of the skin, and/or for reducing the fat mass and the circumference at the hips and thighs, as well as to the corresponding cosmetic and medical methods.

Abstract: Composition containing the combination of (?)-epigallocatechin gallate (EGCG) and lycopene characterized in that the ratio of EGCG to lycopene is in the range of 100:1 to 1:1.

Abstract: Compositions including, as the active ingredients, resveratrol, a derivative, metabolite or analogue thereof, and at least one additional component selected from epigallocatechin gallate (EGCG), genestein, vitamin E, polyunsaturated fatty acids, gamma-linolenic acid and vitamin K are disclosed. Also disclosed, are methods of making such compositions including admixing resveratrol, a derivative, metabolite or analogue thereof, and at least one additional component selected from EGCG, genestein, vitamin E, polyunsaturated fatty acids, gamma-linolenic acid and vitamin K are disclosed. Methods for the treatment or prevention of inflammatory diseases including administering to a subject in need of such treatment resveratrol, a derivative, metabolite or analogue thereof, in combination with at least one additional component selected from epigallocatechin gallate (EGCG), genestein, vitamin E, polyunsaturated fatty acids, gamma-linolenic acid and vitamin K are also disclosed.

Abstract: The invention relates to novel compositions comprising a phenolic compound as well as to the use of these compositions as a medicament, in particular for the manufacture of a nutraceutical or pharmaceutical composition for the treatment, co-treatment or prevention of inflammatory disorders, such as arthritis, asthma, inflammatory bowel diseases, inflammatory diseases of the skin (e.g., psoriasis, eczema, atopic dermatitis, sunburn) and chronic inflammatory disorders, such as atherosclerosis, heart diseases, metabolic syndrome X, cancer, Alzheimer's disease and pre-stages thereof such as mild cognitive impairment. Also, the invention relates to the use of a cosmetic composition comprising a phenolic compound for the cosmetic treatment, co-treatment or prevention of inflammation of the skin, in particular for the cosmetic treatment, co-treatment or prevention of sunburn or of impure skin.

Abstract: The present invention relates to the use of compounds of the formula (I) wherein the clotted line is an optional bond; R1 is butyl or butyryl if R2 is hydroxyl but is butyl if R2 is hydrogen; or R1 and R2 taken together are 1-butylidene optionally substituted by hydroxyl, methyl, or 3-(?,?-dimethylacrylyloxy)-pentylidenyl; X is a residue selected from the group consisting of X1, X2, X3, X4, and X5; wherein X is X2, X3 or X5 if the dotted line in formula (I) is absent; and X is X1, X4 or X5 if the dotted line signifies a bond in formula (I) above; R3 is hydroxyl or butyryl; and n is 1 or 2, as agents for the prevention, control and treatment of conditions requiring modulation of inflammation in mammals. In another aspect, the present invention relates to the use of compounds of the formula (I) as active ingredients in the manufacture of medicaments/compositions for the prevention, control and treatment of conditions requiring modulation of inflammation.

Abstract: The invention relates to novel compositions comprising magnolol and honokiol wherein the mol ratio of magnolol to honokiol is less than 0.6 as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.

Abstract: The present invention relates to novel compositions comprising magnolol and/or honokiol and glucosamine as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.

Abstract: The present invention relates to novel compositions comprising magnolol and/or honokiol and chondroitin as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.

Abstract: The present invention relates to new methoxylated aromatic compounds. It also relates to novel compositions comprising methoxylated aromatic compounds as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.

Abstract: Compositions comprising, as the active ingredients, resveratrol, a derivative, metabolite or analogue thereof, and at least one additional component selected from EGCG, genistein, vitamin E, polyunsaturated fatty acids, gamma-linolenic acid and vitamin K are disclosed. The compositions exert an antiinflammatory effect and may be a food or beverage or a supplement therefor; or may be a pharmaceutical composition.